Vivo Bio Tech Limited has successfully completed the allotment of 90,000 equity shares through the conversion of warrants issued on a preferential basis. The pharmaceutical company announced this development in its regulatory filing dated January 06, 2026.

Share Allotment Details

The company allotted 90,000 equity shares of ₹10 each at an issue price of ₹45 per share, which includes a premium of ₹35 on each equity share. The allotment was made upon receipt of application money totaling ₹30,37,500, representing 75% of the total issue price.

Allottee Information

The entire allotment of 90,000 equity shares was made to Kompella Lopa Mudra, who belongs to the promoter group category. This preferential allotment strengthens the promoter group's stake in the company.

Impact on Share Capital

Following this allotment, Vivo Bio Tech Limited's issued and subscribed share capital has increased significantly. The company's total share capital now stands at ₹22,19,06,280, divided into 2,21,90,628 equity shares of ₹10 each.

This warrant conversion represents a strategic capital raising exercise by the company, providing additional funds while maintaining promoter group participation. The transaction was completed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring proper regulatory disclosure to stakeholders.

Vivo Bio Tech Limited has announced a significant milestone in its growth trajectory, securing a pre-clinical testing contract valued at ₹10.75 crores. The contract, awarded in collaboration with a leading Indian pharmaceutical and agro-chemical company, positions Vivo Bio Tech among an elite group of Contract Research Organizations (CROs) in India.

Contract Details

The newly secured contract spans up to two years and involves comprehensive pre-clinical safety and regulatory studies for a novel molecule. The scope of work includes:

• Toxicity studies across multiple endpoints
• Mutagenicity evaluations to assess genetic safety
• Ecotoxicology studies for environmental risk assessment
• Comprehensive analytical services

All studies will be conducted under Section 9(3) requirements, with regulatory submissions to the Central Insecticides Board & Registration Committee (CIBRC)—India's apex body for approvals.

Regulatory Compliance and Industry Standing

This contract demonstrates Vivo Bio Tech's capability to deliver integrated pre-clinical solutions that meet both national and international regulatory standards. By undertaking this comprehensive mandate, the company joins a select group of CROs in India with the infrastructure and scientific expertise to handle such complex projects.

Management Commentary

Mr. Chandrasekar Patnaik, Chief Business Officer of Vivo Bio Tech Limited, commented on the achievement: "This milestone reaffirms Vivo Bio Tech's scientific and technical excellence and strengthens our positioning as a trusted research partner for the global life sciences industry. It represents a major step forward in our mission to deliver innovative, reliable, and sustainable research services."

Strategic Implications

The contract underscores Vivo Bio Tech's growing leadership across pharmaceuticals, agrochemicals, biotechnology, and environmental sciences. It aligns with the company's long-term vision of evolving from a drug discovery services provider into a strategic co-innovator with large pharma and biotech companies.

By enabling safer and more effective products to reach global markets, Vivo Bio Tech is paving the way for future collaborations in joint drug discovery and milestone-driven partnerships. This positions the company as a benchmark for next-generation CROs in the industry.

Conclusion

The securing of this significant contract not only boosts Vivo Bio Tech's financial outlook but also enhances its reputation in the pre-clinical research domain. As the company continues to expand its capabilities and secure high-value contracts, it is well-positioned to capitalize on the growing demand for comprehensive pre-clinical testing services in the pharmaceutical and agrochemical sectors.